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Cyclin D1 positive plasma 
cell myeloma
To the Editor: Cyclin D1 ams
plification is known to be associs
ated with mantle cell lymphoma. 
However, it can be oversexpressed 
in other hematological malignans
cies such as plasma cell myeloma. 
Conflicting data are reported on 
the clinical significance of cyclin D1 
amplification in plasma cell myelos
ma. Given the significant differencs
es in diagnosis, therapy and progs
nosis, awareness of cyclin D1 overs
expression in plasma cell myeloma 
is important to avoid diagnostic 
pitfalls or confusion, particularly in 
patients with unusual presentation 
or with morphologic variations.
A 69syearsold woman presented 
initially with pancytopenia with a 
hemoglobin of 5.6 g/dL, a white 
cell count of 2.9×109/L, and plates
let of 50×109/L. Her medical hiss
tory was unremarkable. Clinical 
and laboratory workup revealed 
hypogammaglobulinemia, normal 
renal function and normal serum 
calcium. Immunofixation of serum 
showed monoclonal lambda light 
chain restriction. A bone marrow 
biopsy was carried out to stage this 
patient. The differential diagnos
sis included lowsgrade B cell lyms
phoma and plasma cell neoplasms. 
Bone marrow biopsy demonstrated 
a hypercellular marrow infiltrated 
by small cells having a plasmacys
toid appearance, most of which 
had an eccentric nucleus (Figure 
1). Immunohistochemistry pers
formed on a decalcified bone mars
row biopsy showed that the cells 
were strongly positive for lambda 
indicating lambda light chain res
striction (Figure 2). The cells were 
focally positive for CD20 (Figure 
3), diffusely positive for cyclin D1 
(Figure 4) and BCL2 protein. The 
infiltrating neoplastic cells were 
also positive for CD56 (Figure 5) 
in a significant proportion of the 
neoplastic cells. The neoplastic cells 
were negative for LCA, CD3, CD5, 
CD79a, CD43, BCL6, CD10 and 
TRAP. Cytogenetics and polys
merase chain reaction failed to 
demonstrate t (11,14) or cyclin D1 
amplification due to degradation of 
DNA material.
Plasma cell myeloma is a neos
plasm that accounts for up to 
15% of hematologic malignancies 
in adults. The median age of ons
set is 66 years. The most common 
presenting symptoms of multiple 
myeloma are fatigue, bone pain, 
anemia and recurrent infections. 
Hypercalcemia is found in one 
fourth of patients, and the serum 
creatinine level is elevated in one 
half. Conventional radiography 
shows skeletal abnormalities in 
approximately 80% of patients. 
The M protein can be detected by 
serum protein electrophoresis in 
82% of patients and by immunos
fixation in 93%. Approximately 
3% of multiple myeloma cases have 
no detectable M protein on serum 
or urine immunofixation and are 
called nonsecretory plasma cell mys
eloma.1,2 The diagnosis of plasma 
cell myeloma requires criteria that 
must be present in a symptomatic 
patient. A minimum of one major 
and one minor criterion or three 
minor criteria must be present. 
The major criteria includes marrow 
plasmacytosis (>30%), plasmacys
toma on biopsy, and Mscomponent 
as follows in serum: IgG>3.5 g/dL, 
IgA>2 g/dL, or in urine: >1 g/24 h 
of BencesJones protein. The minor 
criteria includes marrow plasmacys
tosis (10% to 30%), Mscomponent 
present but less than above, lytic 
bone lesions and reduced normal 
immunoglobulin (<50% normal).1 
The major differential diagnosis 
includes MGUS, smoldering (ass
ymptomatic) multiple myeloma, 
primary amyloidosis, and solitary 
plasmacytoma.1 Plasma cell myelos
ma is usually an incurable disease 
with median survival being approxs
imately 3 years with chemotherapy, 
with 10% survival for 10 years with 
best results in younger patients 
who undergo bone marrow transs
plant. The prognostic factors in 
plasma cell myeloma are stage of 
disease, overall health of the pas
tient, renal function, hemoglobin, 
serum calcium, lytic bone lesions, 
amount of the Mscomponent betas
2smicroglobulin, plasmablastic 
morphology, Kis67 and estimation 
of degree of marrow replacement 
by plasma cells in marrow core bis
opsies.1 Cyclin D1 expression is not 
included in the WHO guidelines 
as a prognostic marker. 
A literature review of cyclin D1 
revealed by immunohistochemiss
try positive staining for cyclin D1 
is seen in 24% to 30% of plasma 
cell myeloma cases.3s6 Cyclin D1 is 
oversexpressed in plasma cell mys
eloma in 32% to 43%of cases using 
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Figure	5.	The majority of the infiltrating cells are positive for 
CD56, original magnification, X200.
Figure	1.	H&e showing hypercellular bone marrow, infiltrated 
by sheets of cells having plasmacytoid appearance, original 
magnification, X100.
Figure	2.	lambda light chain restriction demonstrated by 
immunohistochemistry, original magnification, X200.
Figure	3.	The cells are focally positive for CD20, original 
magnification, X200.
Figure	4.	The cells are positive for cyclin D1 showing mainly 
nuclear and variable cytoplasmic staining, original magnification, 
X200.
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polymerase chain reaction (PCR) 
or florescence on situ hybridization 
(FISH).4,6s8 There is conflicting 
data on the clinical significance of 
cyclin D1 deregulation in plasma 
cell myeloma. Some studies have 
shown that cyclin D1 analysis can 
provide prognostic information 
while others have concluded that 
oversexpression does not constitute 
a specific group and is not a progs
nostic marker by itself.3s11 Cyclin 
D1 oversexpression can be caused 
by t (11;14)(q13;q32), trisomy 11, 
extra copies of Bscell leukemia/
lymphomas1 (BCLs1/CCND1), 
and other unknown mechanisms.7,10 
Given the significant differences in 
diagnosis, therapy and prognosis, 
awareness of cyclin D1 oversexpress
sion in cases of plasma cell myelos
ma will help to avoid misdiagnosis 
of such cases especially when facing 
cases with unusual presentation or 
morphologic variants. 
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